Paschka et al. found in their study of 805 AML patients that IDH mutations predicted reduced relapse-free and overall survival in favorable risk NPM1mutated/FLT3-ITDwildtype AML (5-year OS was 41% compared with 65% in IDHwildtype patients (P = 0.03)) [60], a finding replicated by Marcucci et al. [66]. This evidence concerns the gene FLT3 and acute myeloid leukemia.